Innogen’s Newly Approved GLP-1 Contender Girds For China Ozempic Battle

insulin injection
Innogen's Diabegone is a newly approved homegrown contender to Novo Nordisk's Ozempic in China's domestic market. • Source: Shutterstock

More from China

More from Business